HI-6 Dimethanesulfonate (DMS) and Atropine Sulfate Reconstitution Autoinjector Device (RAD) Feasibility Assessment
Solicitation number W6369-26-A112
Publication date
Closing date and time 2026/06/16 14:00 EDT
Last amendment date
Description
The Department of National Defence (DND), specifically the Canadian Forces Health Services
(CFHS), has a requirement for the services of a Contractor to test and evaluate the feasibility of
manufacturing HI-6 DMS and atropine sulfate drug products in a reconstitution autoinjector device
(RAD).
The scope of this requirement is to conduct a feasibility assessment using an existing prototype
of a RAD with the configuration of HI-6 DMS in the dry chamber (500 mg +/- 25%) and 1 mL
atropine (2 mg/mL) in the liquid chamber.
The work will involve the following:
• Project Management.
• Analytical Method Development.
• Material Processing and Performance Assessments.
• Mixing and Drug Delivery Model.
• Sterilization Impact Assessment.
Contract duration
The estimated contract period will be 12 month(s).
Trade agreements
-
Please refer to tender description or tender documents
Reason for limited tendering
A contracting officer can use limited tendering for specific reasons outlined in the applicable trade agreements. The reason for this contract is described below:
-
Exclusive Rights
Contact information
Contracting organization
- Organization
-
Department of National Defence (DND)
- Address
-
101 Colonel By Drive
Ottawa, Ontario, K1A 0K2Canada
- Contracting authority
- Alan Escobedo Fox
- Email
- Alan.escobedofox@forces.gc.ca
Bidding details
| Document title | Amendment no. | Language | Unique downloads | Date added |
|---|---|---|---|---|
| ACAN - W6369-26-A112 - HI-6 DMS and Atropine RAD Feasibility Assessment.pdf | This document was removed on 2026/06/02 | |||
| PAC - W6369-26-A112 - Évaluation de faisabilité de DAR d'HI-6 DMS et de médicaments à base de sulfate d'atropine.pdf | This document was removed on 2026/06/02 | |||
| ACAN - W6369-26-A112 - HI-6 DMS and Atropine RAD Feasibility Assessment.pdf | 002 | EN | 23 | 2026/06/02 |
| PAC - W6369-26-A112 - Évaluation de faisabilité de DAR d'HI-6 DMS et de médicaments à base de sulfate d'atropine.pdf | 002 | FR | 4 | 2026/06/02 |